Wortmannin inhibits K562 lukemic cells by regulating PI3k/Akt channel in vitro

Abstract

The inhibitory effect of wortmannin on leukemic cells and the possible mechanisms were examined. K562 cells were treated with wortmannin of various concentrations (3.125–100 nmol/L) for 0–72 h. MTT assay was used to evaluate the inhibitory effect of wortmannin on the growth of K562 cells. Cell apoptosis was detected by both Annexin-V FITC/PI double-labeled cytometry and transmission electron microscopy (TEM). The expression of p-Akt, T-p-Akt, NF-κBp65 and IKK-κB was determined by Western blotting and reverse transcription-polymerase chain reaction (RT-PCR). Our results showed that wortmannin obviously inhibited growth and induced apoptosis of K562 cells in vitro in a time- and dose-dependent manner. The IC₅₀ value of wortmannin for 24 h was 25±0.14 nmol/L. Moreover, wortmannin induced K562 cells apoptosis in a dose-dependent manner. TEM revealed typical morphological changes of apoptosis in wortmannin-treated K562 cells, such as chromatin condensation, karyopyknosis, karyorhexis and apoptotic bodies. Additionally, several important intracellular protein kinases such as p-Akt, NF-κBp65 and IKK-κB experienced degradation of various degrees in a dose-dependent manner both at protein level and transcription level when cultured with wortmannin, but the expression of total Akt showed no change. It is concluded that wortmannin can inhibit the proliferation and induce apoptosis of K562 leukemia cells possibly by down-regulating the survival signaling pathways (PI3K/Akt and NF-κB channels).

Keywords

wortmannin / K562 cell / p-AKT / NF-κB / IKK-κB

References

[1] OlsenB.B., Bjørling-PoulsenM., GuerraB.. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action. Int J Biochem Cell Biol, 2007, 39(1): 227-237

[2] RudeliusM., PittalugaS., NishizukaS., et al.. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood, 2006, 108(5): 1668-1676

[3] FillmoreG.C., WangQ., CareyM.J., et al.. Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma, 2005, 46(12): 1765-1773

[4] PriullaM., CalastrettiA., BrunoP., et al.. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate, 2007, 67(7): 782-789

[5] MartelliA.M., NyåkernM., TabelliniG., et al.. Phosphoinositide 3-kinase/Akt signaling pathway and its theraeutical implications for human acute myeloid leukemia. Leukemia, 2006, 20(6): 91-98

[6] TangJ.M., HeQ.Y., GuoR.X., et al.. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 2006, 51(2): 181-191

[7] GeorgeP., BaliP., AnnavarapuS., et al.. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105(4): 1768-1776

[8] LiaoY., GrobholzR., AbelU., et al.. Increase of Akt/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer, 2003, 107(4): 676-680

[9] HsuJ., ShiY., KrajewskiS., et al.. The Akt kinase is activated in multiple myeloma tumor cells. Blood, 2001, 98(9): 2853-2855

[10] NakanishiK., SakamotoM., YamasakiS., et al.. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer, 2005, 103(2): 307-312

[11] WipfP., HalterR.J.. Chemistry and biology of wortmannin. Org Biomol Chem, 2005, 3(11): 2053-2061

[12] WuC., HuangJ.. Phosphatidylinositol 3-kinase/AKT mammalian target of rapamycin pathway is essential for neuroendocrine diferentiation of prostate cancer. J Biol Chem, 2007, 282(6): 3571-3583

[13] HuangX.L., CuiG.H., ZhouK.Y., et al.. Correlation of PI3K-Akt signal pathway to apoptosis of tumor cells. Chin J Cancer (Chinese), 2008, 27(3): 331-336

[14] GrandageV.L., GaleR.E., LinchD.C., et al.. PI3-kinase/Akt is constitutively active in primary acute myeloid leukemia cells and regulates survival and chemoresistance via NF-κB, MAP kinase and p53 pathways. Leukemia, 2005, 19(4): 586-594

[15] ZhangC., YangN., ZhangX.W., et al.. Advances in kinase inhibitors targeting PI3K/Akt-mTOR signal transduction pathway. Chin Oncol (Chinese), 2006, 16(12): 1064-1070

[16] XuQ., SimpsonS.E., SciallaT.J., et al.. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003, 102(3): 972-980

[17] WestfllS.D., SkinnerM.K.. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther, 2005, 4(11): 1764-1771

[18] PanwalkarA., VerstovsekS., GilesF.J.. Mammalian target of rapamyein inhibition as therapy for hematologic malignancies. Cancer, 2004, 100(4): 657-666

[19] XieX., GaoQ., WangY.L., et al.. Inhibition of PI3 K/PKB signal pathway improves chemotherapeutic effect on gastric carcinoma cell lines. Chin Pharmacol Bull (Chinese), 2008, 24(12): 1666-1670

[20] KarinM., CaoY., GretenF. R., et al.. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2002, 2(4): 301-310

[21] BaldwinA.S.. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest, 2001, 107(3): 241-246

[22] KaltschmidtB., KaltschmidtC., HofmannT.G., et al.. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem, 2000, 267(12): 3828-3835

[23] BhartiA.C., AggarwalB.B.. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol, 2002, 64(5–6): 883-888

[24] PohT.W., PervaizS.. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res, 2005, 65(14): 6264-6274

[25] OhtaT., OhnfiehiM., HayasakaT., et al.. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in vivo ovarian cancer models. Endocrinology, 2006, 147(4): 1761-1769